Login to Your Account



Clinic Roundup


Tuesday, June 28, 2011
Mimetogen Pharmaceuticals Inc., of Montreal, said Phase II data for MIM-D3 in dry eye disease showed the drug was well tolerated and significantly improved signs and symptoms of dry eye at the low and high doses. Detailed data will be presented at a scientific conference. MIM-D3 is a small-molecule mimetic of nerve growth factor.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription